Discovering new antimicrobial agents

被引:165
作者
Moellering, Robert C., Jr. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
Drug discovery; New antimicrobials; Antibacterial targets; Bacterial genomics; Membrane-active drugs; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITY; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; PSEUDOMONAS-AERUGINOSA; ANTIBACTERIAL ACTIVITY; ANTIINFECTIVE THERAPY; ANTIFUNGAL ACTIVITY; BAD BUGS; ANTIBIOTICS; MECHANISM;
D O I
10.1016/j.ijantimicag.2010.08.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although there has been a relentless increase in resistance to antimicrobial agents amongst important bacterial pathogens throughout the world, it is well known that the number of new antimicrobial agents being brought to the market has undergone a steady decline in the past several decades. There are a number of reasons for this, which are detailed in this article, but there is also a great deal of continuing research to find new effective antimicrobials, much of it now being carried out in academic centres and especially in small biotechnology companies, rather than by large pharma. Whilst classic screening methods and chemical modification of known antimicrobial agents continue to produce potential leads for new antimicrobial agents, a number of other approaches are being investigated. These include the search for potentiators of the activity of known antimicrobial agents and the development of hybrid agents, novel membrane-active drugs, and inhibitors of bacterial virulence and pathogenesis. A number of new bacterial targets are also being exploited, as are bacteriophages and their lytic enzymes. Given the amount of investigation presently underway, it is clear that although the antibiotic pipeline is not as promising as it was half a century ago, it is far from dry. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:2 / 9
页数:8
相关论文
共 62 条
[1]   Mechanism of action of oritavancin and related glycopeptide antibiotics [J].
Allen, NE ;
Nicas, TI .
FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532
[2]   In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms [J].
Almer, LS ;
Hoffrage, JB ;
Keller, EL ;
Flamm, RK ;
Shortridge, VD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2771-2777
[3]  
[Anonymous], 2006, LANCET INFECT DIS, V6, P751
[4]   Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates [J].
Arhin, Francis F. ;
Draghi, Deborah C. ;
Pillar, Chris M. ;
Parr, Thomas R., Jr. ;
Moeck, Gregory ;
Sahm, Daniel F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4762-4771
[5]   Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis [J].
Balaban, N ;
Giacometti, A ;
Cirioni, O ;
Gov, Y ;
Ghiselli, R ;
Mocchegiani, F ;
Viticchi, C ;
Del Prete, MS ;
Saba, V ;
Scalise, G ;
Dell'Acqua, G .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (04) :625-630
[6]   Two-component signal transduction as a target for microbial anti-infective therapy [J].
Barrett, JF ;
Hoch, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1529-1536
[7]  
Bertrand D, 2010, ANTIMICROB AGEN 0920
[8]   Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic [J].
Billeter, Marianne ;
Zervos, Marcus J. ;
Chen, Anne Y. ;
Dalovisio, Joseph R. ;
Kurukularatne, Changa .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (04) :577-583
[9]   Antibacterial lysine analogs that target lysine riboswitches [J].
Blount, Kenneth F. ;
Wang, Joy Xin ;
Lim, Jinsoo ;
Sudarsan, Narasimhan ;
Breaker, Ronald R. .
NATURE CHEMICAL BIOLOGY, 2007, 3 (01) :44-49
[10]   In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor [J].
Bonnefoy, A ;
Dupuis-Hamelin, C ;
Steier, V ;
Delachaume, C ;
Seys, C ;
Stachyra, T ;
Fairley, M ;
Guitton, M ;
Lampilas, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :410-417